Montelukast Sodium Chewable Tablets are suitable for the prevention and long-term treatment of asthma in children aged 2 to 14 years, including the prevention of daytime and nighttime asthma symptoms, the treatment of aspirin sensitive asthma patients, and the prevention of exercise induced bronchoconstriction. It is suitable for relieving symptoms caused by seasonal allergic rhinitis. In asthma, leukotriene mediated effects include a series of airway responses, such as bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil aggregation. In allergic rhinitis, the nasal mucosa will release cysteine leukotriene related to the symptoms of allergic rhinitis in both the rapid phase and the delayed phase reactions after allergen exposure. Intranasal cysteine leukotriene stimulation will increase nasal airway resistance and symptoms of nasal obstruction. Monroester has a high affinity and selectivity for the cysteine leukotriene receptor, and can effectively inhibit the physiological effects produced by the binding of cysteine leukotriene and type I cysteine leukotriene receptor without any receptor activation.
